BioLogix bags $6M for oncology drug, names new CEO
Biopharm company BioLogix raised $6 million in first-round equity and debt financing from Essex Woodlands Health Ventures and New Science Ventures. The money will be used to continue development of its top cancer-fighting compound, but a second round is already in the works.
So far the Palo Alto, Calif.-based firm has brought in $40 million. It hopes to take enough in its next fund-raising effort by early 2009 to push the drug into clinial testing, setting… Continue Reading
Achronix nabs $43M for gate array technology
Achronix Semiconductor Corp. recently closed $43 million of a large, still open $52 million second round of financing. Argonaut Private Equity led the tranche, which also included existing investors Battery Ventures, New Science Ventures, Easton Capital Investment Group and Entrepia Ventures. These contributors helped the San Jose, Calif. company hit $25.4 in its first round last January. The company plans to use its new funds to develop a new generation of products.
The round is being… Continue Reading
Life sciences briefing: Thursday, Feb. 21, 2008
TODAY’S HEADLINES:
Compact ultrasound maker Zonare Medical raises $30M (VentureWire)
TherOx raises $30M for hypersaturated-oxygen devices (peHUB)
Accumetrics, antiplatelet-drug diagnostic maker, raises $29M (release)
Population Genetics takes in £3.8M for massively parallel genome studies (GenomeWeb)
“Brain fitness” trainer Dakim raises $11M (release)
BioIQ, home-diagnostics maker, takes in $2.5M (release)
Hospital med-tracker Sabal Medical raises funds (release)
Seattle’s PharmaIN gets $400K NIH grant for nanoparticle staph drug (PDF release)
SensiGen, molecular-diagnostics developer, receives Michigan state loan (release)
Arcus Ventures aims for $50M fund, targets cancer (VentureWire)
Compact… Continue Reading
Life sciences briefing: Wednesday, Oct. 17, 2007
Featured companies: Algorithme Pharma, Bacchus Vascular, Botaneco, Cubist Pharmaceuticals, Ikonisys, Healthcare Management Systems, Illumigen Biosciences, Kilmer Capital Partners, Medical Specialties Distributors, Metastatix, Microphage, Orthosoft, Thomas McNerney & Partners, TranS1, TriReme Medical, Wren Medical, Zimmer
UPDATE: Expanded TriReme Medical, Ikonisys and TranS1 items.
UPDATE REDUX: Added MicroPhage item.
Stent-maker TriReme Medical sails off with $15.6M — Pleasanton, Calif.-based TriReme Medical, a device maker developing a new type of artery-opening stent for blood-vessel junctions, raised $15.6 million in a third funding… Continue Reading
Life sciences briefing: Friday, Aug. 31, 2007
Featured companies: Aryx Therapeutics, FlowCardia, Graftcath
FlowCardia raises $30M for artery roto-rooters — Sunnyvale, Calif.-based FlowCardia, a medical-device maker building catheter systems that bore holes in blood clots, raised $30 million in a third funding round. Investors included Gilde Healthcare Partners, Life Sciences Partners, Hambrecht & Quist Capital Management, New Science Ventures, Frazier Healthcare Ventures, JP Morgan Partners, Pappas Ventures, Rockport Venture Partners and Gold Hill Capital. The funding is intended to speed commercialization of the company’s… Continue Reading
Life sciences briefing: Monday, Aug. 6, 2007
(UPDATED at 5:05 p.m. PDT; see below.)
(As part of my ongoing effort to strike the right balance between keeping up with venture-business news and writing more analysis, I’m inaugurating a daily briefing that will collect deal-related news items from the life sciences in one place. I’ll continue updating this post throughout the day as the news dictates. Comments on this or any other feature of this blog are always welcome; sound off below. For more on… Continue Reading
BioVex raises $22M for cancer-killing viruses
Woburn, Mass.-based BioVex, a biotech working on new ways to attack cancer and infections, raised $22 million in a fifth funding round. Triathlon Medical Ventures led the round, joined by New Science Ventures, Forbion Capital Ventures, Avalon Ventures, Credit Agricole Private Equity, GeneChem Management, Innoven Partners and Scottish Equity Partners.
BioVex is developing so-called oncolytic viruses, which are designed to infect and destroy tumor cells — long a promising but never-proven anti-cancer technique. The company put… Continue Reading
Achronix raises large $25.4 million first round for multi-GHz chip technology
Achronix Semiconductor, a San Jose company developing “multi-GHz Field Programmable Gate Array (FPGA)” technology, has raised a $25.4 million first round of venture backing.
New Science Ventures (of New York) and Battery Ventures led the round, which also included Entrepia Ventures and Easton Capital Investment Group.
The company says the there is a $20 billion-plus market in the “high-performance segment of global ASIC/ASSP/FPGA.”
Here’s the full statement.